Barbara E. Bierer
Haematologist-oncologist and research-ethics leader whose early lab work helped show how rapamycin acts on immune cells
Professor of Medicine, Harvard Medical School · Faculty Director, MRCT Center of Brigham and Women's Hospital and Harvard
Portrait: Harvard Medical School Center for Bioethics
Barbara Bierer is Professor of Medicine at Harvard Medical School and a haematologist-oncologist at Brigham and Women's Hospital. She co-founded and directs the Multi-Regional Clinical Trials (MRCT) Center of Brigham and Women's Hospital and Harvard, and she was the hospital's Senior Vice President for Research from 2003 to 2014.
In the Atlas she is senior author of PRI1992 in Science, written with John Avruch's group. It showed that rapamycin switches off the 70-kDa S6 kinase, one of the first readouts that tied the drug to a specific signalling pathway, years before mTOR itself was found.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 1992 | M | Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase PRI1992 Senior author: rapamycin inactivates the 70-kDa S6 kinase, an early readout of the then-unknown TOR pathway (cells). |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Barbara E. Bierer.
ShowHide
- Joseph Avruch Showed in 1998 that amino acids, not only insulin, are needed for mTOR to activate S6K1 and 4E-BP1. His Massachusetts General Hospital group, with Kazuyoshi Yonezawa's lab in Kobe, then co-discovered raptor in 2002 and found that Rheb binds mTOR directly
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.